- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
From Motley Fool
Ocugen Stock: Bull vs. Bear
November 20, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
From Benzinga
3 Biotech Stocks That Have More Than Tripled so far This Year
November 18, 2021
From Motley Fool
European Regulator Votes Down Biogen's Alzheimer's Drug
November 17, 2021
Tickers
BIIB
From Benzinga
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
November 17, 2021
From Benzinga
Could Eli Lilly Leapfrog Biogen in This Market?
November 17, 2021
From Motley Fool
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
November 16, 2021
From Benzinga
President Biden Nominates Robert Califf As New FDA Commissioner: Report
November 12, 2021
From Benzinga
Why Are Biogen Shares Gaining Today?
November 12, 2021
From Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
From Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
From Benzinga
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
November 11, 2021
From Motley Fool
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
From Benzinga
3 Vaccine Stocks With Big Opportunities Outside of COVID-19
November 11, 2021
From Motley Fool
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
From Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
November 09, 2021
From Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
From Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
From Benzinga
What Investors Should Like About Eli Lilly's Q3 Update
November 04, 2021
From Motley Fool
Healthcare Stocks Subject to Government Policy
November 02, 2021
From Benzinga
Cassava Stock Could Jump More Than 200 Times
November 01, 2021
From InvestorPlace
Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
October 29, 2021
Tickers
BIIB
From Motley Fool
Down 76%: Is Cortexyme Stock a Bargain?
October 28, 2021
From Motley Fool
Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
October 28, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.